Literature DB >> 26469867

Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhage.

Florent Delbos1, Gérald Bertrand2, Laure Croisille1, Hélène Ansart-Pirenne1, Philippe Bierling1,3, Cécile Kaplan2.   

Abstract

BACKGROUND: In Caucasians, fetal/neonatal alloimmune thrombocytopenia (FNAIT) is most frequently caused by maternal alloimmunization against the human platelet antigen HPA-1a. The most serious complication of severe FNAIT is intracranial hemorrhage (ICH). ICH mainly occurs in utero; therefore, there is a need to identify noninvasive predictive factors of ICH to facilitate early identification of this condition and to determine response to maternal therapy. STUDY DESIGN AND METHODS: We studied gynecologic and immunogenetic variables of severe cases of anti-HPA-1a FNAIT within three groups: Group I, FNAIT without ICH; Group II, FNAIT with ICH; and Group III, suspected FNAIT cases without detectable maternal anti-HPA-1a alloantibodies.
RESULTS: ICH was associated with a poor outcome because it led to death in 59% of cases. Multigravida (two or more pregnancies) was overrepresented in Group II, consistent with the high concentrations of maternal HPA-1a alloantibody and the frequent detection of a strong newborn-specific HLA class I antibody response at delivery. The proportion of HLA-DRB4*01:01P (*01:01 or *01:03) women was similar in Groups I and II, but this allele was overrepresented in Group III, in which FNAIT was less severe than in the other two groups. Finally, antenatal intravenous immunoglobulin therapy tended to be more effective in HLA-DRB3*01:01(+)/HLA-DRB4*01:01P(+) women than for HLA-DRB3*01:01(+)/HLA-DRB4*01:01P(-) women.
CONCLUSION: The number of gestations is a predictive factor of ICH in anti-HPA-1a-alloimmunized women. Maternal immunogenetic variables should be investigated in the context of maternal immunization and may predict response to maternal therapy in subsequent pregnancies.
© 2015 AABB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26469867     DOI: 10.1111/trf.13274

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome.

Authors:  Jens Kjeldsen-Kragh; Dean A Fergusson; Mette Kjaer; Lani Lieberman; Andreas Greinacher; Michael F Murphy; James Bussel; Tamam Bakchoul; Stacy Corke; Gérald Bertrand; Dick Oepkes; Jillian M Baker; Heather Hume; Edwin Massey; Cecile Kaplan; Donald M Arnold; Shoma Baidya; Greg Ryan; Helen F Savoia; Denise Landry; Nadine Shehata
Journal:  Blood Adv       Date:  2020-07-28

2.  HLA-DRB3*01:01 exhibits a dose-dependent impact on HPA-1a antibody levels in HPA-1a-immunized women.

Authors:  Jens Kjeldsen-Kragh; Thomas L Titze; Benedicte Alexandra Lie; John T Vaage; Mette Kjær
Journal:  Blood Adv       Date:  2019-04-09

3.  The effect of antenatal magnesium sulfate on intraventricular hemorrhage in premature infants: a systematic review and meta-analysis.

Authors:  Yousef Moradi; Rozhin Khateri; Ladan Haghighi; Shoaib Dehghani; Shiva Mansouri Hanis; Mehrdad Valipour; Zahra Najmi; Zahra Fathollahy; Meisam Allahmoradi; Kamyar Mansori
Journal:  Obstet Gynecol Sci       Date:  2020-06-24

4.  Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT).

Authors:  Jason H Karnes; Christian M Shaffer; Robert Cronin; Lisa Bastarache; Silvana Gaudieri; Ian James; Rebecca Pavlos; Heidi E Steiner; Jonathan D Mosley; Simon Mallal; Joshua C Denny; Elizabeth J Phillips; Dan M Roden
Journal:  Pharmacotherapy       Date:  2017-09-04       Impact factor: 4.705

Review 5.  Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.

Authors:  Heidi Tiller; Anne Husebekk; Maria Therese Ahlen; Tor B Stuge; Bjørn Skogen
Journal:  Int J Womens Health       Date:  2017-04-19

6.  Neonatal alloimmune thrombocytopenia caused by anti-HPA antibodies in pregnant Chinese women: a study protocol for a multicentre, prospective cohort trial.

Authors:  Li Chen; Zhiwei Liu; Tiemei Liu; Xianjun Ma; Meiying Rao; Yongjun Wang; Bo Sun; Wen Yin; Jun Zhang; Beizhan Yan; Xiaojuan Li; Qiushi Wang; Lei Zhang; Jun Wen; Fenghua Liu; Peng Wang; Yaming Wei; Yuanshuai Huang; Jiang Wu; Yi Guo; Yinlan Kang; Xiaochuan Song; Xiangfu Liu; Genling Zhang; Tingting Xie; Yonggeng Chen; Xiaojing Zeng; Zhongjun Li
Journal:  BMC Pregnancy Childbirth       Date:  2017-08-31       Impact factor: 3.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.